DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell ...

The same Nobel-winning mRNA technology that helped curb the Covid-19 pandemic may be poised to transform cancer care.

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...

The authoritative peer-reviewed source for research, analysis, and advances on the therapeutic role of cytokines and IFNs. Suppressor of Cytokine Signaling (SOCS) 1 is a key negative regulator of ...

The regulation of type I interferon (IFN-1) signaling is crucial for fine-tuning the innate immune response to combat pathogens, fight cancer and prevent autoimmune diseases. Disrupted IFN-1 signaling ...

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led ...

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...